SH2D4B Activators
SH2D4B activators are compounds that modulate the activity of the SH2 domain-containing 4B protein, a member of the Src homology 2 (SH2) domain-containing family. The SH2D4B protein plays a role in various intracellular signaling pathways that are crucial for the regulation of cellular processes. SH2 domains are known for their ability to bind to specific phosphotyrosine-containing sequences in other proteins, which facilitates protein-protein interactions. These interactions are integral to the transduction of signals within cells, affecting a multitude of signaling pathways. The activation of SH2D4B by certain molecules can lead to changes in its binding affinities or its ability to interact with other proteins within the cell, thereby modulating the signaling pathways in which it is involved. These pathways can influence cellular behaviors such as growth, differentiation, and migration.
Activators of SH2D4B may have a chemical structure that enables them to interact directly with the SH2D4B protein, perhaps binding to its active site or to a regulatory region, altering its conformation, and affecting its interaction with other proteins. The activation of SH2D4B could also occur indirectly through the modulation of upstream or downstream molecules within the signaling cascade that subsequently affect SH2D4B function. The precise molecular mechanisms of these activators and their interactions with SH2D4B are often elucidated through biochemical and biophysical studies, which may include techniques such as X-ray crystallography, NMR spectroscopy, or mass spectrometry. These studies help in understanding how SH2D4B activators affect the protein's structure and function at the molecular level, providing insights into the protein's role within cellular signaling networks.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, which by preventing the PI3K-mediated phosphorylation of PIP2 to PIP3, can result in an accumulation of PIP2. PIP2 may then serve as a docking site for SH2D4B, which does not directly activate SH2D4B but can enhance its proximity to other signaling molecules and potential substrates. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 inhibits Src family kinases, which can attenuate downstream signaling that may otherwise compete with or regulate SH2D4B activity. With reduced Src kinase activity, SH2D4B's role in signal transduction pathways, such as cell adhesion or migration, may be enhanced. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin, through its receptor, initiates a cascade that activates the PI3K/Akt pathway. The activation of this pathway can lead to changes in the cellular localization and function of SH2D4B, enhancing its role in metabolic signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor which, by blocking the MAPK/ERK pathway, may lead to compensatory signaling through alternative pathways involving SH2D4B, thereby potentially enhancing its signaling role. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor; however, at low concentrations, it may preferentially affect certain kinases over others, which could shift cellular signaling dynamics in a way that enhances the role of SH2D4B in cell survival and proliferation pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that, similar to LY294002, can lead to increased levels of PIP2 and alter the localization and activity of SH2D4B within the cell by increasing its interaction with other signaling proteins. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2 which may result in the upregulation of alternative signaling pathways where SH2D4B could play a role, potentially enhancing its activity in these pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol (DAG) analog that activates protein kinase C (PKC). PKC activation may influence SH2D4B activity by modulating the phosphorylation state of proteins within pathways that SH2D4B is involved in. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 increases intracellular calcium levels, which can activate calcium-dependent signaling pathways. SH2D4B may be modulated by these pathways as calcium signaling can affect a broad range of cellular processes, including those involving SH2D4B. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P is a bioactive lipid that activates sphingosine-1-phosphate receptors, potentially influencing SH2D4B activity by altering the cellular context or environment in which SH2D4B operates, such as cell adhesion or migration. | ||||||